INTENSITY THERAPEUTICS, INC. (INTS) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-8.95M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.80× | Operating cash flow / net income. Period ending 2026-06-30. $-8.95M ÷ $-11.16M ≈ 0.80× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -8.95M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -11.16M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-8.95M | (m) | (m) | (m) | (m) | $-11.16M | (m) | (m) | (m) | 0.80× |
| 2026-03-31 | (m) | (m) | $-9.07M | (m) | (m) | (m) | (m) | $-10.69M | (m) | (m) | (m) | 0.85× |
| 2025-12-31 | (m) | (m) | $-9.23M | (m) | (m) | (m) | (m) | $-11.61M | (m) | (m) | (m) | 0.80× |
| 2025-09-30 | (m) | (m) | $-9.50M | (m) | (m) | (m) | (m) | $-11.74M | (m) | (m) | (m) | 0.81× |
| 2025-06-30 | (m) | (m) | $-11.09M | (m) | (m) | (m) | (m) | $-12.58M | (m) | (m) | (m) | 0.88× |
| 2025-03-31 | (m) | (m) | $-12.84M | (m) | (m) | (m) | (m) | $-15.01M | (m) | (m) | (m) | 0.86× |
| 2024-12-31 | (m) | (m) | $-15.22M | (m) | (m) | (m) | (m) | $-16.27M | (m) | (m) | (m) | 0.94× |
| 2024-09-30 | (m) | (m) | $-13.50M | (m) | (m) | (m) | (m) | $-16.26M | (m) | (m) | (m) | 0.83× |
| 2024-06-30 | (m) | (m) | $-14.64M | (m) | (m) | (m) | (m) | $-15.07M | (m) | (m) | (m) | 0.97× |
| 2024-03-31 | (m) | (m) | $-10.67M | (m) | (m) | (m) | (m) | $-13.80M | (m) | (m) | (m) | 0.77× |
| 2023-12-31 | (m) | (m) | $-7.21M | (m) | (m) | (m) | (m) | $-10.54M | (m) | (m) | (m) | 0.68× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $-5.48M | (m) | (m) | (m) | (m) | $-7.58M | (m) | (m) | (m) | 0.72× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |